Approval Year
| Substance Class |
Mixture
Created
by
admin
on
Edited
Sat Dec 16 18:04:24 UTC 2023
by
admin
on
Sat Dec 16 18:04:24 UTC 2023
|
| Record UNII |
808UI9MS5K
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000191281
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
||
|
WHO-VATC |
QJ01XA04
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
||
|
FDA ORPHAN DRUG |
459714
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
||
|
NCI_THESAURUS |
C61101
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
||
|
WHO-ATC |
J01XA04
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
N0000191280
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
PRIMARY | Lipoglycopeptides [Chemical/Ingredient] | ||
|
QQ-102
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
PRIMARY | |||
|
171500-79-1
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
MAJOR COMPONENT STRUCTURE/SEQUENCE | |||
|
Dalbavancin
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
PRIMARY | |||
|
m4070
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
PRIMARY | Merck Index | ||
|
808UI9MS5K
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
PRIMARY | |||
|
C116741
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
PRIMARY | |||
|
CHEMBL3301669
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
PRIMARY | |||
|
777
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
PRIMARY | |||
|
82721
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
PRIMARY | |||
|
DB06219
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
PRIMARY | |||
|
7978
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
PRIMARY | |||
|
808UI9MS5K
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
PRIMARY | |||
|
SUB26697
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
PRIMARY | |||
|
C469289
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
PRIMARY | |||
|
1539239
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
PRIMARY | RxNorm | ||
|
DALBAVANCIN
Created by
admin on Sat Dec 16 18:04:25 UTC 2023 , Edited by admin on Sat Dec 16 18:04:25 UTC 2023
|
PRIMARY |
All of the following components must be present:
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET ORGANISM->INHIBITOR |
Efficacy and safety profiles of both dalbavancin and oritavancin were the same as vancomycin in the treatment of gram-positive bacterial infections in different clinical settings,
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |